Skip to main content

Table 2 Clinical and biochemical parameters of cases and controls

From: Noninvasive tool for the diagnosis of NAFLD in association with atherosclerotic cardiovascular risk

Variable Cases (n = 60) Controls (n = 30) p
Age (years) 42.1 ± 6.75 42.06 ± 8.1 0.989
SBP (mmHg) 130.17 ± 10.3 121.67 ± 12.2 0.029
DBP (mmHg) 80.70 ± 8.6 76.33 ± 7.7 0.09
ALT (U/L) 39.2 ± 9.3 13.5 ± 3.6 < 0.01
AST (U/L) 34.1 ± 6.73 16.07 ± 3.51 < 0.01
ALP (U/L) 138.4 ± 31.7 134.3 ± 18.0 0.59
T. Bil (mg/dl) 0.675 ± 0.4 0.5 ± 0.4 0.1
D. Bil (mg/dl) 0.3 ± 0.2 0.3 ± 0.35 0.8
Albumin (mg/dl) 4.05 ± 0.39 4.43 ± 0.45 0.01
PT (seconds) 12.69 ± 0.82 12.58 ± 0.42 0.55
INR 1.06 ± 0.12 0.99 ± 0.08 0.03
FBS (mg/dl) 97.77 ± 14.17 79.53 ± 8.28 0.945
HbA1c 5.35 ± 1.16 5.09 ± 0.43 0.282
Fasting insulin (μU/ml) 8.75 ± 5.05 8.6 ± 1.9 0.866
HOMA-IR 1.95 ± 1.8 2 ± 0.67 0.539
Triglycerides (mg/dl) 124.37 ± 29.4 92.8 ± 21.58 < 0.01
Cholesterol (mg/dl) 173.3 ± 40.3 141.3 ± 15.5 < 0.01
HDL (mg/dl) 46.2 ± 7.9 54.7 ± 7.3 0.001
LDL (mg/dl) 99.5 ± 32.5 87 ± 17 < 0.01
  1. SBP systolic blood pressure, DBP diastolic blood pressure, ALT alanine transaminase, AST aspartate transaminase, T. Bil total bilirubin, D. Bil direct bilirubin, PT prothrombin time, INR international normalized ratio, FBS fasting blood sugar, HbA1c glycated hemoglobin, HOMA-IR homeostasis model assessment-insulin resistance, HDL high-density lipoprotein, LDL low-density lipoprotein